RANDLAB. Veterinary Medicines Product Range GLOBAL EDITION EDITION GLOBAL

Transcription

1 GLOBAL EDITION RANDLAB Veterinary Medicines Product Range 2016 GLOBAL EDITION

2 Quality, Service, Value and Care. Respiratory Products Contents Randlab s Commitment to Excellence Veterinary Medicines Product Range Ulcer Treatments Ulcershield 4 Gastropell Daily 5 Gastropell Forte 6 High Performance Joint Therapies Matrix 6000 I.V. Injection 7 Equinate I.V./I.A. Injection 8 Equinate I.V. Injection 9 Arthropen Vet 250 Injection 10 Arthropen Vet Injection (Dog) 11 Respiratory Medicines Airway Tmps 12 Airway Gel 13 Bromo Tmps 14 Colix Injection 15 Anti-Inflammatory Equine Bute Paste 16 Platinum Bute I.V. Injection 17 Meloxicam Injection 18 Meloxicam Paste 19 Our Global Network for International Orders 20 Randlab has based its business on four core pillars: Quality, Service, Value and Care. Our commitment to these four pillars have ensured that we can continue to grow, research new products and deliver products that meet the needs of horse owners and equine veterinarians alike. Sedative and Analgesic Antibiotics Sed-Ace 21 Stilator 22 Mobitor 23 Sedator 24 Equine Metronidazole Paste 25 Enro 50 Injectable Solution 26 Enro 100 Injectable Solution 27 Quality Our commitment to quality starts with the sourcing of only the finest raw materials and pharmaceutical grade ingredients for our products. We manufacture all of our products in facilities that are GMP approved through the Australian regulator, the APVMA. We carefully follow each batch of our manufactured product with strict Quality Assurance (QA) testing in government approved independent laboratories. Worldwide product registrations (where available) are part of our quality control and also serve to protect our innovative medicines. Service We have a simple philosophy with our service the customer comes first and the relationship is of utmost value to Randlab. We pride ourselves on the personal level of service that we offer our veterinarian, wholesaler and institutional partners throughout the world. If you have yet to use our products, contact us to discuss how our products and service can help you and your business. Value Randlab understands that owning horses for whatever need can be expensive. We also understand and support equine veterinarians by providing our products at a cost competitive level. Care Randlab cares very deeply about its involvement in the equine and veterinary community globally. We are active in selected equine and veterinary charities throughout the world. You can find Randlab at every major equine veterinary conference and further education event. Our catalogue has been designed to provide an easy reference to the veterinary medicine products available from Randlab. Full details are also available on our website. Australia New Zealand Singapore Malaysia United Arab Emirates Argentina Belgium Japan Wormers Breeding Other Company Information Rotamectin 28 Terminator 29 Ovu-Mate 125 ml 30 Ovu-Mate 1 Litre 30 Ovu-Mate Injection 31 Ovu-Late 32 Cattle-Mate 33 Intra-Log Coticosteroid 34 Medicaine Local Anaesthetic Injection 35 Pro-Cardia 365 Once-a-year Heartworm Preventative for Dogs 36 Vetedine Ointment 37 Zoldronic Bone Modifier 38 Supplements 40 Partnering for Success 42 Global Growth 43 Randlab s Commitment to Veterinarians 44 More Information 45 How to Order 45 International Contacts 46 2 This document and all its contents is copyright Randlab Veterinary Medicines

3 4 Ulcer Treatments Respiratory Ulcer Treatments Products Ulcershield Oral Paste APVMA Approval No / (Australia) ACVM No. A10916 (New Zealand) Omeprazole paste Gastropell Daily Oral Paste PATENTED FORMULATION APVMA Approval No /0909 (Australia) ACVM No. A10165 (New Zealand) SENASA No (Argentina) Enteric-coated Omeprazole in an oral paste for the treatment and prevention of gastric ulcers in horses After administering the initial dose use remaining product within 1 month. Treatment Dose - 4 mg/kg. Adult horses (600 kg) give 6 ml daily for 28 days (1 ml per 100 kg). For the stabled performance horse given two or three feeds a day, the stomach is left for long periods without ingestion of feed and without the mat of ingesta on the surface of the stomach fluid that helps to contain the acidic fluid. This exposure to acid is then increased during intense exercise when the stomach volume is reduced to half that of the rested horse and the gastric acid is forced into the squamous region where it attacks the stomach lining. Omeprazole 370 mg/g Pack of 6 x 33g multi-dose syringes Pharmacology Omeprazole is a proton-pump inhibitor. Omeprazole suppresses gastric acid by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the parietal cell. Omeprazole will block gastric acid secretion irrespective of the stimulus. Maximum acid suppression occurs after 3-5 days of treatment. Prevention Dose - 1 mg/kg. Adult horses (600 kg) give 1.5 ml daily for 28 days (0.25 ml per 100 kg). Set dial-a dose syringe to required volume and administer into the side of the mouth far back into the pocket between the teeth and the cheek or over the back of the tongue. The product is very sticky so ensure that it is applied onto the internal parts of the mouth, not just dropped into the oral cavity. Immediately raise the horse s head for a few seconds after dosing to ensure the full dose has been swallowed. Safety Directions May irritate the eyes and skin. Avoid contact with eyes and skin. Wash hands after use. Omeprazole 50 mg/ml Enteric-coated Pack of 5 x 30mL syringes Pail of 50 x 30mL syringes Gastropell Daily contains omeprazole, a dose-dependant inhibitor of gastric acid secretion. Clinical trial data indicates that Gastropell Daily will inhibit gastric acid secretion to maintain gastric acidity at a non-aggressive level, which allows existing ulcers to heal within two weeks of commencing treatment, and that a reduced daily dose will prevent the recurrence of ulcers The stomach lining is in a continual process of erosion and repair depending on the acidity of the stomach fluid and the horse/s feeding and exercise pattern. The pattern of regular sessions of intense training and long periods of the day without ingestion of feed is, however, well tolerated by the performance horse in training if gastric acid secretion is blocked by Gastropell Daily every day and the gastric fluid is then not aggressive to the stomach lining. Dosage and Administration Dosage and administration: Give orally via syringe. Discard unused portions within 3 days after completion of the treatment program. Foals - 2 ml/100 kg BW (1.0 mg/kg BW) once daily as directed by a veterinarian. Adult Horses - Treatment Dose - 10 ml/500 kg BW (1.0 mg/kg BW) once daily for two weeks followed by daily maintenance dosing. Maintenance Dose - 5 ml/500 kg BW (0.5 mg/kg BW) once daily while horses remain in training, or as directed by a veterinarian. Gastropell Daily 10 ml/500 kg BW can provide rapid healing of stomach ulcers while horses remain in training, which may be associated with the improvement in clinical signs within two weeks of commencing treatment. When left untreated, ulcers can recur within two weeks with a severity and across an area equivalent to that prior to treatment. Available data indicates that regular daily maintenance dosing at a reduced rate prevents the recurrence of ulcers. Features Of Gastric Ulceration In Horses Clinical signs of gastric ulceration include depressed appetite or inappetence, recurrent colic, intermittent loose faeces, chronic diarrhoea, poor hair coat, poor body condition or poor performance. Signs in foals include depressed appetite or inappetence, teeth grinding, dribbling saliva, diarrhoea, sternal recumbency or weakness. For accurate diagnosis direct endoscopic examination of the gastric mucosa is recommended. Safety To Horses Ulcershield has a wide safety margin in horses and foals and can be used in foals from one month old. Ulcershield can be safely administered to stallions used for breeding. Safety in pregnant or lactating mares has not been established. The safety of Ulcershield for longer than 91 days treatment has not been determined. Concomitant Therapy Ulcershield can be used concomitantly with other medications including anthelmintics, antibiotics, non-steroidal anti-inflammatories and other commonly administered veterinary preparation. Meat Withholding Period: NOT TO BE USED in horses intended for human consumption. regarding medication should be observed. Disposal: Dispose of empty syringe by wrapping with Storage: Store below 30 C (Room temperature). Actions Omeprazole is an inhibitor of gastric acid secretion. When given on a daily basis, omeprazole inhibits the enzyme system regarded as the acid (proton) pump within the gastric mucosa of the stomach by binding to the enzyme and blocking the first step of acid production. Even though it is dosed orally, Gastropell Daily does not act directly on the stomach fluid as it is ingested. The drug passes through the stomach to the small intestine, where it is absorbed and travels via the bloodstream to the acid secreting cells of the stomach. The powerful antisecretory effect of Gastropell Daily causes a dramatic reduction in the acidity of stomach fluid within days of commencing treatment, and because the gastric fluid is no longer irritating to the stomach lining, ulcers then heal spontaneously within two weeks. Continuation with reduced daily dosing then prevents ulcers from recurring. The lower region of the stomach is permanently exposed to gastric acid and has a prostaglandin protective mechanism, which guards against acid attack. The squamous mucosa in the upper region of the stomach has, however, no inherent protection and frequent splashing with gastric acid fluid soon erodes the lining to cause spot lesions, which can develop into deep haemorrhaging ulcers within weeks. Safety Directions May irritate the eyes and skin. Avoid contact with eyes and skin. Wash hands after use. Meat Withholding Period: NOT TO BE USED in horses intended for human consumption. regarding medication should be observed. with Storage: Store below 30 C (Room temperature). 4 5

4 6 Ulcer Treatments High Performance Respiratory Products Joint Therapies Gastropell Forte ORAL PASTE FOR HORSES PATENTED FORMULATION ACVM No. A10775 (New Zealand) Enteric-coated Omeprazole in an oral paste for the treatment and prevention of gastric ulcers in horses performance horse given two or three feeds a day, the stomach is left for long periods without ingestion of feed and without the mat of ingesta on the surface of the stomach fluid that helps to contain the acidic fluid. This exposure to acid is then increased during intense exercise when the stomach volume is reduced to half that of the rested horse and the gastric acid is forced into the squamous region where it attacks the stomach lining. The stomach lining is in a continual process of erosion and repair depending on the acidity of the stomach fluid and the horse/s feeding and exercise pattern.the pattern of regular sessions of intense training and long periods of the day without ingestion of feed is, however, well tolerated by the performance horse in training if gastric acid secretion is blocked by Gastropell Forte every day and the gastric fluid is then not aggressive to the stomach lining. PRECAUTIONS - If used in performance animals, regulations of relevant authorities Give orally via syringe. Discard unused portions within 3 days after completion of the treatment program. Matrix 6000 I.V. INJECTION APVMA Approval No /62606 (Australia) ACVM No. A (New Zealand) For IV treatment of lameness in horses associated with non-infectious acute synovitis ACTIVE Pentosan Omeprazole Polysulfate 100 mg/ml Sodium Enteric-coated 250mg/mL 12 30mL x 6mL Single Vials syringe per outer carton and 50mL Single Vial Gastropell Forte contains omeprazole, a dose-dependant inhibitor of gastric acid secretion. Clinical trial data indicates that Gastropell Forte will inhibit gastric acid secretion to maintain gastric acidity at a non-aggressive level, which allows existing ulcers to heal within two weeks of commencing treatment, and that an ongoing daily dose will prevent the recurrence of ulcers. Actions Omeprazole is an inhibitor of gastric acid secretion. When given on a daily basis, omeprazole inhibits the enzyme system regarded as the acid (proton) pump within the gastric mucosa of the stomach by binding to the enzyme and blocking the first step of acid production. Even though it is dosed orally, Gastropell Forte does not act directly on the stomach fluid as it is ingested. The drug passes through the stomach to the small intestine, where it is absorbed and travels via the bloodstream to the acid secreting cells of the stomach. The powerful antisecretory effect of Gastropell Forte causes a dramatic reduction in the acidity of stomach fluid within days of commencing treatment, and because the gastric fluid is no longer irritating to the stomach lining, ulcers then heal spontaneously within two weeks. Continuation with daily dosing then prevents ulcers from recurring. The lower region of the stomach is permanently exposed to gastric acid and has a prostaglandin protective mechanism, which guards against acid attack. The squamous mucosa in the upper region of the stomach has, however, no inherent protection and frequent splashing with gastric acid fluid soon erodes the lining to cause spot lesions, which can develop into deep haemorrhaging ulcers within weeks. For the stabled 6 Adult Horses: Treatment Dose: 10 ml/500 kg BW (2.0 mg/kg BW) once daily for two weeks followed by daily maintenance dosing. Maintenance Dose: Horses out of competition - 5mL/500 kg BW (1.0mg / kg BW) Horses in competition - 10 ml/500 kg BW (2.0 mg/kg BW) once daily while horses remain in training, as directed by a veterinarian. Gastropell Forte 10 ml/500 kg BW can provide rapid healing of stomach ulcers while horses remain in training, which may be associated with the improvement in clinical signs within two weeks of commencing treatment. When left untreated, ulcers can recur within two weeks with a severity and across an area equivalent to that prior to treatment. Available data indicates that regular daily maintenance dosing at a reduced rate prevents the recurrence of ulcers. Safety Directions May irritate the eyes and skin. Avoid contact with eyes and skin Wash hands after use. Meat Withholding Period: NOT TO BE USED in horses intended for human consumption. with Storage: Store below 30 C (Room temperature). Sodium Hyaluronate 10 mg/ml 6 x 6mL vials per outer carton 12 x 6mL vials per outer carton MATRIX 6000 I.V. is indicated in the treatment of lameness in horses due to non-infectious acute synovitis possibly associated with early equine degenerative joint disease. Read the enclosed product leaflet before using this product. Intravenous route 4-6 ml (40-60 mg) per adult horse ( kg). Strict aseptic technique should be observed when injecting MATRIX 6000 I.V. Radiographs should be taken prior to administration to eliminate joint fractures or advanced degenerative joint disease. This product does not contain any antimicrobial preservative. Any solution remaining in the vial after administration of the required dose should be discarded. Intravenous Route Dosage: Adult horse ( kg). Administer 4 6 ml (40 60 mg) intravenously. Treatment may be repeated at weekly intervals for a total of three treatments. To achieve best results in cases of intravenous administration, horses should be rested during treatment and given 7 days stable rest after treatment before gradually resuming normal activity. Meat Withholding Period: Zero (0) days. Disposal: Dispose of empty containers, outer packaging or expired product by wrapping with paper and putting in garbage. Discarded needles/sharps should immediately be placed in a designated and appropriately labelled sharps container. Storage: Store below 25 C (air conditioning). This product does not contain any antimicrobial preservative. Any solution remaining in the vial after administration of the required dose should be discarded. 7

5 8 High Performance Joint Therapies High Performance Respiratory Products Joint Therapies Equinate I.V./I.A. INJECTION APVMA Approval No /50221 (Australia) ACVM No. A10491 (New Zealand) For IV or IA treatment of lameness in horses associated with non-infectious acute synovitis Sodium Hyaluronate 10 mg/ml 12 x 2mL vials per outer carton Description Equinate Injection is a clear colourless solution. It is administered by intra-articular or intravenous injection. The active ingredient is extracted from the capsule of a selected microorganism and purified to produce a pure form of sodium hyaluronate that is essentially free of protein or nucleic acids. The solution is pyrogen free and sterile. It contains no preservative. Each ml of Equinate Injection contains 10 mg of sodium hyaluronate in physiological sodium chloride-phosphate buffer. The ph is adjusted to between 6.5 and 7.0. Chemistry Depending upon the chemical environment in which it is found, the glycosaminoglycan commonly referred to as hyaluronic acid (hyaluronan) can exist as the acid (hyaluronic acid), the sodium salt (sodium hyaluronate), or as the hyaluronate anion. These terms may be used interchangeably but all refer to the glycosaminoglycan composed of repeating subunits of D- glucuronic acid and N-acetyl-D-glucosamine linked together by glycosidic bonds. Since this product originates from a microbial source, there is no potential for contamination with dermatan or chondroitin sulphate or any other glycosaminoglycan. Pharmacology Hyaluronic acid is a naturally occurring substance present in connective tissue, skin, vitreous humour, and the umbilical cord in all mammals and in high concentrations in synovial fluid. It also constitutes the major component of the capsule of certain microorganisms. The hyaluronic acid produced by bacteria is of the same structure and configuration as that found in mammals. It is widely accepted that sodium hyaluronate restores lubrication of the joint fluid and regulates the normal cellular constituents. This effect decreases the impact of exudation, enzyme release, and subsequent degradation of joint integrity. Hyaluronate molecules are long chains which form a filter matrix interspersed with normal cellular fluids. This further supplements the viscoelastic properties of normal joint fluid. Sodium hyaluronate exerts a slight anti-inflammatory action by limiting the movement of granulocytes and macrophages into the joint. Equinate is indicated in the treatment of lameness in horses due to non-infectious acute synovitis possibly associated with early equine degenerative joint disease. Strict aseptic technique should be observed when injecting Equinate Injection. Radiographs should be taken prior to administration to eliminate joint fractures or advanced degenerative joint disease. This product does not contain any antimicrobial preservative. Any solution remaining in the vial after administration of the required dose should be discarded. Intravenous Route - 4mL (2 vials) (40mg) per adult horse ( kg). Treatment may be repeated at weekly intervals for a total of three treatments. Intra-articular Route - The recommended dosage by intraarticular route is 2mL (1 Vial) (20mg) per adult horse ( kg). Treatment may be repeated at weekly intervals for a total of three treatments. As with any intra-articular procedure, proper injection site disinfection and animal restraint are important. Excess joint fluid should be aseptically removed prior to intraarticular injection. Care should be taken not to scratch the cartilage surface with the injection needle. Diffuse swelling lasting 24 to 48 hours may result from movement of the needle while in the joint space. To achieve best results in cases of intra-articular or intravenous administration, horses should be rested during treatment and given 7 days stable rest after treatment before gradually resuming normal activity. Meat Withholding Period: Nil. regarding medication should be observed. Disposal: Dispose of empty containers, outer packaging or expired product by wrapping with paper and putting in garbage. Discarded needles/sharps should immediately be placed in a designated and appropriately labelled sharps container. Storage: Store below 25 C (Air conditioning). Protect from light. Equinate I.V. INJECTION APVMA Approval No /1009 (Australia) ACVM No. A10089 (New Zealand) SENASA No (Argentina) For treatment of lameness in horses associated with non-infectious acute synovitis Sodium Hyaluronate 10 mg/ml 12 x 4mL vials per outer carton Description Equinate I.V. Injection is a clear colourless solution. It is administered by intravenous injection. The active ingredient is extracted from the capsule of a selected micro-organism and purified to produce a pure form of sodium hyaluronate that is essentially free of protein or nucleic acids. The solution is pyrogen free and sterile. It contains no preservative. Each ml of Equinate I.V. Injection contains 10 mg of sodium hyaluronate in physiological sodium chloride-phosphate buffer. The ph is adjusted to between 6.5 and 7.0. Chemistry Depending upon the chemical environment in which it is found, the glycosaminoglycan commonly referred to as hyaluronic acid (hyaluronan) can exist as the acid (hyaluronic acid), the sodium salt (sodium hyaluronate), or as the hyaluronate anion. These terms may be used interchangeably but all refer to the glycosaminoglycan composed of repeating subunits of D- glucuronic acid and N-acetyl-D-glucosamine linked together by glycosidic bonds. Since this product originates from a microbial source, there is no potential for contamination with dermatan or chondroitin sulphate or any other glycosaminoglycan. Pharmacology Hyaluronic acid is a naturally occurring substance present in connective tissue, skin, vitreous humour, and the umbilical cord in all mammals and in high concentrations in synovial fluid. It also constitutes the major component of the capsule of certain microorganisms. The hyaluronic acid produced by bacteria is of the same structure and configuration as that found in mammals. It is widely accepted that sodium hyaluronate restores lubrication of the joint fluid and regulates the normal cellular constituents. This effect decreases the impact of exudation, enzyme release, and subsequent degradation of joint integrity. Hyaluronate molecules are long chains which form a filter matrix interspersed with normal cellular fluids. This further supplements the visco-elastic properties of normal joint fluid. Sodium hyaluronate exerts a slight anti-inflammatory action by limiting the movement of granulocytes and macrophages into the joint. Equinate I.V. is indicated in the treatment of lameness in horses due to non-infectious acute synovitis possibly associated with early equine degenerative joint disease. Strict aseptic technique should be observed when injecting Equinate I.V injection. Radiographs should be taken prior to administration to eliminate joint fractures or advanced degenerative joint disease. This product does not contain any antimicrobial preservative. Any solution remaining in the vial after administration of the required dose should be discarded. Intravenous Route - 4 ml (40 mg) per adult horse ( kg). Treatment may be repeated at weekly intervals for a total of three treatments. To achieve best results in cases of intravenous administration, horses should be rested during treatment and given 7 days stable rest after treatment before gradually resuming normal activity. Meat Withholding Period: Nil. regarding medication should be observed. Disposal: Dispose of empty containers, outer packaging or expired product by wrapping with paper and putting in garbage. Discarded needles/sharps should immediately be placed in a designated and appropriately labelled sharps container. Storage: Store below 25 C (Air conditioning). Protect from light. 8 9

6 10 High Performance Joint Therapies High Performance Respiratory Products Joint Therapies Arthropen Vet 250 INJECTION APVMA Approval No /12x6mL/0709 (Australia) ACVM No. A10081 (New Zealand) SENASA No (Argentina) An aid in the treatment of non-infectious inflammatory joint disease in horses Pentosan Polysulfate Sodium 250 mg/ml 12 x 6mL vials per outer carton 50mL single vial Description Arthropen Vet 250 Injection is a sterile solution formulated as an aid in the treatment of non-infectious inflammatory joint disease in horses. Pharmacology Pentosan polysulfate sodium (PPS) is a semi-synthetic polysaccharide with a linear xylan (pentosan) backbone. Xylan is a hemicellulose derived from plant origin by extraction from the cell walls of hardwoods. PPS possesses anti-inflammatory, anti-arthritic and chondroprotective activities. The beneficial effects of pentosan polysulfate sodium in joint disease are due to the following actions: a) Anti-inflammatory activity. b) Inhibition of neutrophil migration into the joint. c) Stimulation of hyaluronic acid synthesis by synovial fibroblasts, resulting in increased volume and viscosity of synovial fluid. d) Stimulation of proteoglycan synthesis by chondrocytes. e) Fibrinolytic activity, resulting in improved circulation to subchondral bone and periarticular structures. Clinical Application Arthropen Vet 250 Injection is indicated as an aid in the treatment of non-infectious, inflammatory joint disease in the horse. Clinical applications include the following conditions: osteoarthritis, osteochondritis dissecans (OCD), traumatic joint and periarticular inflammation. If used in performance animals, the regulations of the relevant authorities 10 Contraindicated for use in horses with clotting defects, traumatic haemorrhage, infection, liver/kidney failure, or within 2 days of surgery. Administer by intramuscular or intra-articular injection. Following withdrawal of the first dose, use the remainder of the vial within 28 days or discard the unused portion. Precautions Due to the anti-coagulant properties of PPS, bleeding from local blood vessels following intra-articular administration is more likely if PPS is left in contact with the tissue along the injection track. The following steps are recommended for intra-articular injection of Arthropen Vet 250 Injection: (i) Prepare site as for surgery, avoiding iodine-based skin preparations. Use a neutral, soapless skin cleanser. (ii) A 20 gauge non-cutting needle is suitable for injection. Introduce into the joint space with steady even pressure. (iii) Allow approximately 1 ml of synovial fluid to escape before attaching the syringe containing Arthropen Vet 250 Injection. Withdraw synovial fluid into the syringe if possible before injecting into the joint. (iv) Draw back on the syringe once or twice to mix Arthropen Vet 250 Injection with synovial fluid. (v) Apply a firm elastic bandage around the joint for 3 to 4 hours after injection and keep the horse in a confined space during this time. Careful technique, avoiding tissue damage, and firm postinjection bandaging will minimise the risk of intra-articular haemorrhage, which is the most common cause of acute inflammatory swelling following intra-articular injection. Dosage and Administration Intra-articular - 1mL by aseptic intra-articular injection. Injections may be repeated once weekly for 3 to 4 injections. More than one joint may be treated at a time. The horse should be rested for 2 weeks after the final injection, followed by a further 2 weeks of graded walking exercise before returning to work. Intramuscular - 3mg/kg bodyweight (6mL/500kg horse) by intramuscular injection on four occasions with an interval of 5-7 days between injections. Meat Withholding Period: Nil. Storage: Store between 2 and 8 C (Refrigerate. Do not freeze). Protect from light. Store vials in an upright position. Following withdrawal of the first dose, use the remainder of the vial within 28 days or discard the unused portion. Arthropen Vet INJECTION (DOG) APVMA Approval No /(0208) (Australia) ACVM No. A10024 (New Zealand) SENASA No (Argentina) An aid in the treatment of non-infectious inflammatory joint disease in dogs Pentosan Polysulphate Sodium 100 mg/ml 12 x 10mL vials per outer carton Description Arthropen Vet Injection is a sterile solution formulated as an aid in the treatment of noninfectious inflammatory joint disease in dogs. Pharmacology Pentosan polysulfate sodium is a semi-synthetic polysaccharide polymer that possesses anti-inflammatory, anti-arthritic and chondroprotective properties. These beneficial effects arise from: a) Direct anti-inflammatory activity. b) Inhibition of neutrophil migration into joints. c) Stimulation of hyaluronic acid synthesis by synovial fibroblasts which results in a marked increase in synovial volume and viscosity. d) Stimulation of chondrocytes and the biosynthesis of proteoglycans. e) Strong fibrinolytic activity which improves the circulation of subchondral bone and peri-articular structures. 1. Osteo-arthritis especially in conditions affecting multiple joints. 2. Osteo-chondrosis dissecans. 3. Traumatic joint and peri-articular inflammation in dogs. RESTRAINTS DO NOT USE in food producing species of animals. Contraindicated for use in dogs with clotting defects, traumatic haemorrhage, infection, liver/kidney failure, or within 2 days of surgery. Administer by intramuscular or subcutaneous injection. Following withdrawal of the first dose, use the remainder of the vial within 28 days or discard the unused portion. Administer 3mg/kg on four occasions with an interval of 5-7 days between injections. If used in performance animals, the regulations of the relevant authorities regarding medication should be observed. Meat Withholding Period: DO NOT USE in food producing species of animals. Storage: Store between 2 and 8 C (Refrigerate. Do not freeze). Protect from light. Store vials in an upright position. Following withdrawal of the first dose, use the remainder of the vial within 28 days or discard the unused portion. 11

7 12 Respiratory Products Respiratory Products Airway Tmps Airway Gel APVMA Approval No /500/0807 (Australia) ACVM No. A10158 (New Zealand) Oral bronchodilator and antibacterial for the treatment of respiratory diseases in horses Oral Administration In Horses One level scoop (9g) orally per 250kg bodyweight to be added to feed twice daily for 6 to 10 days. Twice daily dosing is recommended to maintain therapeutic levels of active drugs in all situations. APVMA Approval No /52280 (Australia) ACVM No. A (New Zealand) Oral bronchodilating agent for horses Contraindications - Do not use concomitantly with corticosteroids, prostaglandins, oxytocin and beta adrenergic blocking agents. Discontinue use in pregnant mares at least 7 days prior to expected foaling time. S Clenbuterol Hydrochloride ug/g Sulfadiazine 335 mg/g Trimethoprim 67 mg/g Tips Clenbuterol is a bronchodilator with minimal effect on the cardiovascular system. Clenbuterol also has a stabilising effect on mast cells, preventing the release of histamine, serotonin and bradykinin, therefore has a beneficial effect to clear mucociliary discharge. The spectrum of bacteria sensitive to this antibiotic combination includes; Staphylococci, Streptococci, Fusobacterium, Eneterobacter, Corynebacterium (excluding Rhodococcus equi), Salmonella, Shigella, Klebsiella, Pasteurella, Haemophilus, Proteus spp and most E.coli, some Brucella and Nocardia spp. Most Pseudomonas spp are insensitive. Bacterial culture and sensitivity testing should be carried out in cases of non-responsive or chronic infection. Handling Precautions May be harmful if swallowed. May cause skin irritation. Repeated exposure may cause skin allergy. May cause eye irritation. Avoid inhalation. May cause respiratory sensitisation. Trimethoprim possibly may affect bone. Clenbuterol Hydrochloride 41 µg/ml 230mL tub For oral administration to horses. Acute Conditions - 2 ml/100 kg bodyweight 30 minutes prior to feeding morning and night for 7-10 days. Chronic Conditions ml/100 kg bodyweight 30 minutes prior to feeding morning and night as required to provide long term control of symptoms. Administration - Administer using a 10 ml oral dosage syringe. Insert the syringe nozzle into gel and withdraw required dose. Invert to expel air. Adjust to dose. Scrape off the excess gel adhering to the outside of syringe and nozzle onto inner edge of jar. Insert syringe and nozzle into corner or horse s empty mouth. Direct towards back of tongue, and depress plunger to deposit gel. Lift horse s chin and hold mouth closed for a few seconds to ensure that full dose is swallowed. Reseal jar after use. 500g tub Pharmacology Airway Tmps Oral Powder is formulated for the treatment of respiratory disease in horses caused by organisms susceptible to trimethoprim and sulfadiazine combination therapy. It is for treatment of respiratory conditions characterised by restriction or obstruction of airways, including bronchospasm and obstruction resulting from bacterial and viral infection, bronchitis and bronchopneumonia. Airway Tmps Oral Powder is indicated whenever bronchodilation and antibacterial protection is desirable. Clenbuterol is a sympathomimetic amine that blocks beta2-receptor sites in the body, including those in lungs and uterus. This allows for maximum bronchodilation with improved pulmonary ventilation and mucus clearance without significant effects on the heart and blood vessels. For the treatment of respiratory disease in horses caused by organisms susceptible to a trimethoprim/sulfadiazine combination. Treatment of respiratory conditions characterised by restriction of the airways, including bronchospasm and obstruction resulting from bacterial and viral infection, bronchitis and bronchopneumonia. Indicated where bronchodilation and antibacterial protection is desirable. Contraindications Airway Tmps Oral Powder will potentiate the action of corticosteroids, and antagonise the effects of prostaglandin F2alpha and oxytocin. Beta adrenergic agents adversely affect the action of Airway Tmps. Concurrent treatment of horses with these medications is not recommended. Airway Tmps Oral Powder should not be used in horses during the last 14 days of gestation, as uterine contractions may be prevented. Meat Withholding Period: Nil. Storage: Store below 30 C (Room temperature). Protect from light. As an aid in the treatment of respiratory conditions where bronchodilation or clearance of excess mucus would be beneficial. Pharmacology Clenbuterol is a sympathomimetic amine, with specific Beta 2 receptor agonist activity, to exert a bronchodilatory effect. Clenbuterol has expectorant activity, increasing the volume and, reducing viscosity of mucoid secretions to promote airway clearance. Both these properties make clenbuterol of therapeutic and clinical value in the treatment of respiratory conditions complicated by bronchospasm or build-up of mucus in lower airways in horses. Meat Withholding Period: DO NOT USE in horses that may be slaughtered for human consumption. with Storage: Store below 30 C (Room temperature). Protect from light

8 Respiratory Products Respiratory Anti-Inflammatory Products Bromo Tmps ORAL POWDER APVMA Approval No /500G/0308 (Australia) ACVM No (New Zealand) Treatment of respiratory infections in horses Colix Injection APVMA Approval No /57947 (Australia) An aid in the treatment of non-infectious inflammatory joint disease in horses Bioavailability Pharmacokinetic trials in horses have established that both sulfadimidine and trimethoprim are readily and rapidly absorbed after oral administration and reach therapeutic plasma levels within approximately 30 minutes of administration. Trial results demonstrate that the formulation is efficiently absorbed even when administered with food. Handling Precautions Sulfadimidine may possibly affect development and/or reproduction. Trimethoprim may possibly affect bone. Handle with care. For more information on Bromo Tmps refer to our website. Equine - Musculoskeletal disorders: 1.1 mg per kg (1mL/45kg) bodyweight once daily by I.V. (intravenous) or I.M. (intramuscular) injection for up to 5 days. Alleviation of pain associated with colic mg per kg bodyweight I.V administration is recommended for prompt relief. May be repeated with signs of colic occur. Cause of colic should be determined and treated with concomitant therapy. Bovine - Infectious respiratory conditions, downer cow Syndrome mg/kg I.V. (2 ml/45kg bodyweight). Once daily dosage for 1-3 days. Concomitant anti-infective therapy required in the presence of bacterial infections. Oxytetracycline and tylosin are compatible with flunixin. SEPARATE injections must be given. Footrot and musculoskeletal indications, visceral pain (colic) mg/kg I.M. or I.V. Swine - MMA syndrome: 2.2 mg/kg (2 ml/45kg) by deep I.M. injection (5 cm). One or two injections twelve hours apart. Canine mg per kg bodyweight I.V. (0.2 ml/9 kg bodyweight) once daily for 2-3 days. Dose rate should not be exceeded. Sulfadimidine 430 mg/g Trimethoprim 86 mg/g Bromhexine Hydrochloride 8.6 mg/g 500g tub For the treatment of respiratory infections in horses due to organisms susceptible to the combination of sulfadimidine and trimethoprim. Dosage Frequency MICs of the sulfadimidine-trimethoprim combination vary widely for the range of respiratory pathogens which are of significance in equine respiratory disease. In order to ensure efficacy against the major equine respiratory pathogens, the dose rate of Bromo Tmps Oral Powder has been calculated to produce drug levels which would be therapeutic against those pathogens for which the MIC is greatest. Once daily dosing of Bromo Tmps Oral Powder at recommended dose rates will produce average steady state levels of sulfadimidine/trimethoprim which are effective against many of the major bacterial respiratory pathogens of clinical significance in horses in Australia. Twice daily dosing of Bromo Tmps Oral Powder is recommended in preference to once daily dosing as the minimum (trough) concentrations of sulfadimidine and trimethoprim are potentially subtherapeutic in some individuals for some sensitive pathogens under a once daily dose regimen. For oral administration only. Administer on damp food with honey or molasses. Add one level scoop (12g) per 200kg bodyweight twice daily in feed. Twice daily dosing is recommended to maintain therapeutic levels of active drugs in all situations. Meat Withholding Period: DO NOT USE less than 28 days before slaughter for human consumption. Additional information is listed in the Material Safety Data Sheet available from RANDLAB AUSTRALIA in Australia phone (02) or in New Zealand (09) Storage: Store below 30 C (Room temperature). Protect from light. Keep lid tightly closed. Flunixin Meglumine equivalent to 50 mg/ml Flunixin 100mL vial Contraindications This product is contraindicated for use in cats. The safe use of Colix in pregnant, lactating or breeding dogs has not been established. In the absence of any specific studies in pregnant target animals such use is contraindicated. Equine - For the alleviation of inflammation and pain associated with musculoskeletal disorders and for the alleviation of visceral pain and inflammation associated with colic. Also aids the normalisation of peristalsis. Bovine - As an aid in the management of acute respiratory disease in cattle. As an aid in the management of downer cow syndrome. Swine - As an aid in the treatment of mastitis, metritis, agalactia syndrome (MMA or lactational failure) in sows. Canine - As supportive therapy for arthritis, heat stroke and accident cases. Trade Advice Export slaughter interval - this product does not have an ESI established. For advice on the ESI, contact Randlab on (02) before using the product. Meat Withholding Period: Meat (cattle, pigs) - DO NOT USE less than 7 days before slaughter for human consumption. Meat (horses) - DO NOT USE less than 28 days before slaughter for human consumption. Milk - Milk collected from cows within 36 hours (3 milkings) following treatment MUST NOT BE USED for human consumption or processing. The milk should not be feed to bobby calves. with Storage: Store below 30C (Room Temperature). Do not freeze

9 Anti-Inflammatory Respiratory Anti-Inflammatory Products Equine Bute Paste APVMA Approval No /45232 (Australia) ACVM No. A10324 (New Zealand) Anti-inflammatory, analgesic and antipyretic oral paste for the relief of painful musculoskeletal conditions in horses Clinical Application Phenylbutazone is used for its anti-inflammatory, analgesic and antipyretic activity in the treatment of acute laminitis, bone and joint inflammation, and musculoskeletal disorders, as well as in soft tissue inflammation, tendonitis, acute tenosynovitis, capsulitis and bursitis. Clinical response to the drug can be seen within a few hours of oral dosage, while optimum effects occur approximately 12 hours post administration. Anti-inflammatory, analgesic and antipyretic oral paste for the relief of painful musculoskeletal conditions in horses. Platinum Bute I.V. INJECTION APVMA Approval No /58052 (Australia) For the relief of painful musculoskeletal conditions in horses Adverse reactions Toxic reactions to Platinum Bute IV Injection are uncommon, but may be expressed as oedema of legs, jaundice, blood dyscrasia or gastric irritation. Dosage and Administration Administer by slow intravenous injection of solution at room temperature. HORSES and FOALS Initially 5-10 ml per 225 kg per day. Subsequent doses, depending on response, may be reduced to ml per 225 kg per day. Treatment should be continued for 5-6 days. For oral use only. This product is contraindicated in animals with cardiac, renal or hepatic disorders, blood dyscrasias or preexisting gastrointestinal ulceration. Horses - Administer orally prior to feeding. 4.4 mg/kg (10 ml/450 kg) bodyweight twice daily for the first day; 2.2 mg/kg (5 ml/450 kg) bodyweight twice daily for the next four days; 2.2 mg/kg (5 ml/450 kg) once daily on alternate days or as directed by a veterinarian. Maximum daily dose should not exceed 4 grams (20 ml). Ponies - Administer orally prior to feeding. 2.2 mg/kg (2.5 ml/225 kg) bodyweight twice daily for four days; 2.2 mg/kg (2.5 ml/225 kg) once daily on alternate days or as directed by a veterinarian. Do not exceed the recommended dose, as ponies exhibit an increased sensitivity to the toxic effects of phenylbutazone. Phenylbutazone 200 mg/ml 1 Litre pail 500mL tub Pharmacology Phenylbutazone is a nonsteroidal anti-inflammatory drug (NSAID) with antipyretic and analgesic activity. It binds irreversibly to the enzyme cyclooxygenase, inhibiting its activity in the biosynthesis of prostaglandins. Prostaglandins are the primary mediators of the inflammatory response causing tissue swelling and inflammation, pain, and fever. Further production of prostaglandin cannot occur until new enzyme is synthesized; resulting in a reduced concentration of prostaglandins at inflammatory sites, and reduced inflammatory responses. Phenylbutazone is well absorbed following oral administration. The drug is distributed throughout the body, with highest levels being attained in the liver, lungs, heart, kidneys, and plasma. Phenylbutazone is up to 95% plasma protein bound. The increased vascular permeability to plasma proteins during an inflammatory process results in concentration of phenylbutazone in the inflammatory exudate. The serum half-life of phenylbutazone is dose dependent, ranging in the horse from 3.5 hours at a dose of 2g/450kg to 6 hours at a dose of 8g/450kg. Therapeutic efficacy may last for more than 24 hours, due probably to the irreversible binding of the drug to cyclooxygenase. Phenylbutazone is almost completely metabolised in the horse. The principal metabolites are oxyphenbutazone, with a pharmacological effect similar to phenylbutazone, and the pharmacologically inactive y-hydroxyphenylbutazone. The first of the metabolites to be excreted is y-hydroxyphenylbutazone which can be detected in urine up to 18 hours post administration. Oxyphenbutazone may be detected for at least 96 hours in the horse following a single oral dose. Precautions Phenylbutazone should not be combined with other NSAIDs or other highly protein bound drugs, such as digoxin, warfarin, and sulfonamides. Potential adverse effects of phenylbutazone include anorexia, depression, colic, weight loss, ventral oedema, oral and gastrointestinal lesions including ulcers, and renal papillary necrosis. Ponies exhibit an increased sensitivity to the toxic effects of phenylbutazone. If any of these signs occur, discontinue treatment immediately. Meat Withholding Period: NOT TO BE USED in horses intended for human consumption. NEW ZEALAND INFORMATION: It is a legal requirement that this product is not used in any animal producing or intended to produce food for human consumption. with Storage: Store below 25 C (Air conditioning). Protect from light. Active Constituents Phenylbutazone Sodium 200 mg/ml (equivalent to Phenylbutazone Base 186 mg/ml) Sodium Salicylate 50 mg/ml 100mL single vial Actions Phenylbutazone is a non-steroidal anti-inflammatory and analgesic agent. Sodium salicylate is an antipyretic analgesic agent. The combination of these two drugs provides both rapid action (sodium salicylate) and prolonged effect (phenylbutazone). General Statements For the relief of painful musculoskeletal conditions in horses. Such conditions include arthritis, arthrosis, osteitis, osteoarthritis, bursitis, tendonitis, tenosynovitis and the inflammation of soft tissues and skin. When used for the relief of febrile conditions, treatment of the underlying cause should be provided concurrently with Platinum Bute IV Injection. The safety of Platinum Bute IV has been evaluated at doses of up to 20 ml/225 kg (Day 1) and 10 ml/225 kg (Days 2-5), without any adverse effect. RESTRAINT DO NOT USE in horses intended for human consumption. Contraindications This product is contraindicated for use in horses with serious cardiac, hepatic or renal dysfunction, history of blood disorders (especially haemoglobinuria) or gastro-intestinal disturbances. Meat Withholding Period: NOT TO BE USED in horses intended for human consumption. Storage: Store between 2 and 8 C (Refrigerate. Do not freeze). Protect from light. Store vials in an upright position. Following withdrawal of the first dose, use the remainder of the vial within 4 days or discard the unused portion

10 Anti-Inflammatory Anti-Inflammatory Meloxicam INJECTION APVMA Approval No /57427 (Australia) ACVM No. A10915 (New Zealand) A non-steroidal anti-inflammatory analgesic antipyretic for use in horses Meloxicam 20 mg/ml 100mL single vial Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, antiendotoxic, ant exudative, analgesic and antipyretic properties. HORSES - For single dose rapid initiation of therapy of musculoskeletal disorders and relief of pain associated with colic. SIDE EFFECTS AND OVERDOSING - Subcutaneous as well as intravenous administration is well tolerated in cattle; only a slight transient swelling at the injection site following subcutaneous administration has been reported in approximately 10% of animals treated in clinical studies. In the case of overdosing, a symptomatic treatment should be initiated. Precautions And Contraindications Following withdrawal of the first dose, use the remainder of the vial within 28 days or discard the unused portion. HORSES - The safety of this product in pregnant or lactating horses and in horses of under 6 weeks of age has not been established therefore its use in these classes of horse is contraindicated. Use in animals suffering from haemorrhagic gastrointestinal disorders, impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of individual hypersensitivity to the product is contraindicated. Concurrent administration with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents is contraindicated and should be used with caution in conjunction with other highly protein bound drugs. Discard unused portion after 28 days of first broaching bottle. HORSES - SINGLE USE ONLY by single intravenous injection. 0.6 mg meloxicam/kg bodyweight (i.e. 3.0 ml/100 kg bodyweight). Trade Advice EXPORT SLAUGHTER INTERVAL (ESIs) The ESI on this label was correct at the time of label approval. Before using this product, confirm the current ESI from the manufacturer or the APVMA website ( residues/esi.shtml). Meat Withholding Period: MEAT - DO NOT USE less than 8 days for cattle and 4 days for pigs or 28 days for horses before slaughter for human consumption. MILK - Milk collected from cows within 6 days (12 milking s) of treatment MUST NOT BE USED for human consumption, processing or fed to bobby calves. Storage: Store below 25 C (Air conditioning). Meloxicam PASTE ACVM No. A (New Zealand) A non-steroidal anti-inflammatory analgesic - antipyretic for use in horses Meloxicam 20 mg/ml 230mL tub Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class, which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, antiendotoxic, anti-exudative, analgesic and antipyretic properties. Horses: For daily use for the alleviation of inflammation and the relief of pain in both acute and chronic musculoskeletal disorders and the relief of pain associated with colic. Precautions Avoid use in any dehydrated, hypovolaemic or hypotensive horses as there is a potential risk of renal toxicity. Precautions And Contraindications HORSES: The safety of this product in pregnant or lactating horses and in horses of under 6 weeks of age has not been established therefore its use in these classes of horse is contraindicated. Use in animals suffering from haemorrhagic gastrointestinal disorders, impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of individual hypersensitivity to the product is contraindicated. Concurrent administration with glucocorticosteroids, other nonsteroidal anti-inflammatory drugs or with anti-coagulant agents is contraindicated and should be used with caution in conjunction with other highly protein bound drugs. Dosage Use within 28 days of opening. HORSES: Daily dose of 0.6 mg meloxicam/kg bodyweight (i.e. 3.0 ml/100 kg bodyweight) for up to 14 days. Meat Withholding Period: HORSES: DO NOT USE less than 28 days before slaughter for human consumption. with Storage: Store below 25 C (Room Temperature). Use entire product within 28 days of opening

11 Sedative and Analgesic Our Global Network Randlab has a global distribution network of partners commited to serving veterinarians New Zealand Singapore Malaysia United Arab Emirates Argentina Belgium Japan International Ordering orders@randlab.com.au or info@randlab.com.au Call Debra in our Sydney office (61-2) Fax your order (61-2) Sed-Ace ORAL GEL ACVM No. A (New Zealand) As an aid in quieting excitable, nervous, unruly or hard to handle horses. Acepromazine Maleate12 mg/ml 30mL adjustable dose syringe Uses Orally administered acepromazine maleate to provide a dose-dependent tranquiliser, relaxant and sedative effects in horses. SED-Ace Oral Gel provides a safe, convenient and effective method of tranquilising and sedating horses. Acepromazine maleate mediates hypotensive, hypothermic and antispasmodic actions. It has little, if any, analgesic effect, so that painful procedures must be avoided, particularly where animals are known to have unpredictable temperaments. Tranquilising Action - Low doses of oral acepromazine maleate promote a mild tranquilising effect, useful as an aid in quietening excitable, nervous and hard-to-handle horses. It can provide a beneficial calming effect during handling, transport and confinement. It reduces excitability, whilst retaining co-ordination and awareness of environment. Examples of Use of SED-Ace Oral Gel An aid in training horses. To calm nervous horses and reduce stress (alleviates the use of whips, hobbles and twitches). In minor surgical procedures in which an anaesthetic is not required. As a preanaesthetic, to augment action and permit smooth induction and recovery. In non surgical procedures such as shoeing and dentistry. Handling mares during breeding. Horses that have wounds which cannot heal due to constant irritation (biting, licking etc.) After major surgery to reduce straining. Useful aid in the treatment of colic and tetanus. To calm horses during transport. Contraindicated for use in breeding stallions. Paralysis of the retractor penis muscle has been associated with the use of parenterally administered acepromazine maleate in horses. Acepromazine maleate is hypotensive, and must be administered with caution to animals exhibiting symptoms of debilitation, congestive heart failure, sympathetic blockage, hypovolaemia or shock. Tranquilisers are additive to the functions of other depressants, and will potentiate general anaesthesia. Do not use this product in conjunction with organophosphates and/or procaine hydrochloride, as it may enhance activity and potential toxicity. Adrenaline (epinephrine) is contra-indicated in the treatment of acute hypotension produced by over-dosage of acepromazine maleate, since further depression of systemic blood pressure can result. Other pressoramines, such as noradrenaline (norepinephrine) or neosynephrine should be administered to reverse hypotensive effects. To be given orally to horses. The required dosage of SED-Ace Oral Gel may vary depending on the individual temperament of the animal. When administered to male horses (geldings or stallions), use the lowest dose recommended to produce the required effect. Horses 4-10 ml per 450 kg bodyweight 0.13 mg to 0.26 per kg bodyweight. The tranquilisation effect may be more pronounced if feed and water intake is limited during a period of five hours before dosing. On an empty stomach, tranquilisation effect will be apparent in horses within minutes, and with duration of up to 12 hours. On a full stomach, full tranquilisation effect will be apparent within minutes or longer, with duration of 12 hours. For best results, avoid excitement or stimulation of the animal prior to administration. During sedation, horses will normally retain visual and auditory acuity, so that loud sounds and rapid movements should be avoided. Exceeding the recommended dosage will not necessarily intensify the effect of this product. The following administration technique will ensure accurate dosage with minimal wastage of paste. Remove cap from nozzle. Turn ring to required dose setting which should be on the left of the ring. Insert the nozzle into the animal s empty mouth. Direct towards back of tongue, and depress plunger to deposit paste. Lift animal s chin and hold mouth closed for a few seconds to ensure that full dose is swallowed. Replace cap on nozzle after use. Meat Withholding Period: 28 days. with Storage: Store below 30 C (room temperature)

12 Sedative and Analgesic Sedative and Analgesic Stilator INJECTION Mobitor INJECTION Sedative and analgesic for dogs and cats Medetomidine Hydrochloride 1 mg/ml 10mL single vial Restraint: NOT TO BE USED in food producing species of animals. Contra-indications: The use of Stilator in pregnancy has not been monitored in sufficient animals and is, therefore, not recommended. Stilator should not be used in conjunction with sympathomimetic amines. Precautions Care should be taken with the use of Stilator in animals with cardiovascular, respiratory, liver and kidney disease, hypotension, shock or in poor general health. The concomitant use of other CNS depressants should be expected to potentiate the depressant effects of either product, and appropriate dose adjustment should be made. Side-effects Due to the mechanism of action of Stilator, heart rate and body temperature decrease. Treated animals should be kept warm in an even temperature for 12 hours after sedation. Blood pressure will initially increase and then return to normal or slightly below. This is accompanied by a compensatory decrease in heart rate. Some dogs and most cats will vomit, (particularly if recently fed), 5 to 10 minutes post-injection. Some cats may also vomit at recovery. Occasionally muscle jerking in limbs has been observed. For parenteral use by intramuscular or intravenous injection in dogs and intramuscular injection in cats. Animal Effect Dose µg/kg Quantity Slight sedation ml/10 kg Dog im/iv Cat im Moderate to deep sedation and ml/10 kg analgesia Pre-anaesthesia ml/10 kg Moderate sedation ml/5 kg Deep sedation ml/5 kg NOTE: To get an equal effect, the higher recommended doses per kg body weight have to be used in small dogs compared to large dogs. Maximal effect is obtained within 10 to 15 minutes. Duration of the clinically useful effect is dose related 30 to 120 minutes (sedation), 30 to 150 minutes (analgesia). The dose can be repeated if necessary. The duration of analgesia is generally shorter than the duration of sedation. Both analgesic and sedative effects are reversed with the use of Mobitor (atipamezole). Overdosage In case of overdosage, Mobitor can be used. The administration of anticholinergic agents (atropine or glycopyrrolate) to treat bradycardia either simultaneously with medetomidine or following medetomidine could lead to adverse cardiovascular effects. Antagonist: The effects of Stilator can be reversed with Mobitor. with Storage: Store below 30 C (room temperature). Protect from light. Do not freeze. In-use shelf life: This product is stable for 3 months after initial broaching. Discard any remaining product after that date. Pro-Cardia, Stilator and Mobitor are products registered to Ferrari Animal Health, Specific Reverser of Medetomidine and Dexmedetomidine for Dogs and Cats For parenteral use in reversing and abolishing the effects of medetomidine hydrochloride and dexmedetomidine hydrochloride in dogs and cats Contraindications: Atipamezole has only been administered to a limited number of pregnant dogs so cannot be recommended during pregnancy. Precautions Due to the potent pharmacological activity of atipamezole, skin contact with this product should be avoided. Wipe off excess spillage on skin of animals. Side effects: In dogs, a transient hypotensive effect has been observed with atipamezole HCl injections during the first 10 minutes post-injection. Vomiting and panting after atipamezole injection have been reported, but these effects appear to be rare. Transient over-alertness and tachycardia may be observed after a possible overdosage. Dosage and Administration This product is to be used by the intramuscular (IM) route of administration. The following dosage should be adhered to when administering Mobitor to counter the effects of medetomidine hydrochloride: Animal Dose Quantity The following dosage should be adhered to when administering Mobitor to counter the effects of dexmedetomidine hydrochloride: Animal Dose Quantity Dog 10 times that of previous 0.5 mg/ml dexmedetomidine hydrochloride dose ( µg/ kg atipamezole hydrochloride) Cat 5 times that of previous 0.5 mg/ml dexmedetomidine hydrochloride dose (200 µg/kg atipamezole hydrochloride) The same volume as the 0.5 mg/ml dexmedetomidine hydrochloride dose Half the volume of the 0.5 mg/ml dexmedetomidine hydrochloride dose. Mobitor is quickly absorbed and it is recommended that at these dose levels it can be administered 15 to 60 minutes after administration of medetomidine hydrochloride or dexmedetomidine hydrochloride. a subsidiary of Randlab Veterinary Medicines Pty Ltd. a subsidiary of Randlab Veterinary Medicines Pty Ltd Dog Cat Atipamezole Hydrochloride 5 mg/ml 10mL single vial 5 times that of previous 1 mg/ml medetomidine hydrochloride dose ( µg/kg atipamezole hydrochloride) 2.5 times that of previous 1 mg/ml medetomidine hydrochloride dose ( µg/kg atipamezole hydrochloride) Pro-Cardia, Stilator and Mobitor are products registered to Ferrari Animal Health, The same volume as the medetomidine hydrochloride dose Half the volume of the medetomidine hydrochloride dose with Storage: Store below 30 C (room temperature). Protect from light. Do not freeze. In-use shelf life: This product is stable for 3 months after initial broaching. Discard any remaining product after that date.

13 Sedative and Analgesic Respiratory Antibiotic Products Sedative/Analgesic for CATTLE AND Horses Sedator ACVM No. A (New Zealand) For mild to heavy sedation and for analgesia in cattle and horses and for control of pain in uncomplicated colic in horses Detomidine Hydrochloride 10 mg/ml 5mL single vial Sedator is a dose controlled sedative and analgesic. It may be used to facilitate examinations, x-rays, minor surgical operations, transport etc. It may be used to control pain including that of the uncomplicated equine colic case. Sedator has a role in providing prolonged analgesia (upto 12 hours) in horses for example with an accident case. For analgesia in COLIC in horses the recommended dose is 20-40μg/kg BW ( mL/kg BW) until diagnosis is confirmed. Sedator is a sedative and analgesic that may be used to facilitate: Examinations e.g. Endoscopy, rectal palpation, gynaecological examinations and x-rays. Minor surgical procedures e.g. Treatment of wounds, removal of skin tumours, hoof care and castration. Treatment and medication e.g. use of nasogastric tube and shoeing. In painful procedures detomidine should be used in combination with an analgesic or a local anaesthetic. Contraindications As the safety of Sedator during pregnancy and lactation has not been adequately documented, its use is not recommended during the last month of pregnancy. Intravenous potentiated sulphonamides are contraindicated in sedated or anaesthetised horses as potentially fatal dysrhythmias may occur. Precautions Sedator may cause penile relaxation. Use with caution on male animals, particularly during breeding. Clinicians should anticipate the occasional tendency of the animal s head to drop under the influence of Sedator and the subject should be accommodated appropriately. Immediately following administration there may be a tendency to stagger, particularly if high dose rates are employed. Fasting prior to Sedator sedation is not necessary. The animal should not be fed until the effect of the drug has worn off. The safe handling of horses and cattle can be improved with Sedator. Although the animal is easy to handle under Sedator sedation, normal restricting methods are recommended. Local anaesthetics can be used when required for painful procedures, particularly surgery, as the duration of analgesia from Sedator may not equate with the duration of sedation. A risk/benefit assessment should be undertaken by a veterinarian before using this product in animals suffering from cardiac disease (with pre-existing bradycardia and risk of atrioventricular block), respiratory, liver or renal insufficiencies or shock. If cattle lie down avoid ruminal bloat and aspiration of feed or saliva by maintaining in sternal recumbency during and following treatment with head and neck lowered. Overdosage and Side Effects The symptoms may be relieved by atropine or specific alpha-2 antagonist. Harmful side effects have not been observed. Sympathomimetic properties, particularly at higher doses, may include piloerection, sweating, diuresis and occasional slight tremors. Horses and Cattle: Administration is by slow intravenous or the intramuscular route. Dose Effect Effects begin μg/ ml/ (mins) kg 100 kg Easy to handle Easy to handle Prolonged effect Strong effect Duration of action (hrs) Other effects Slight teetering Slight teetering Teetering, sweating, piloerection, muscle spasms Strong teetering, sweating, piloerection The effects begin soon after IV administration. Tissue tolerance to Sedator is good. For analgesia in COLIC until diagnosis is confirmed, recommended dose is μg/kg BW ( ml/100 kg BW). The full analgesic effect is established by 5 15 minutes following administration. If the desired level of sedation is not achieved following administration of a low dose, a further, additive, dose may be given. When using Sedator extra fuss should be avoided. Meat Withholding Period: It is an offence for users of this product to cause residues exceeding the relevant MRL in the New Zealand (Maximum Residues of Agricultural Compounds) Food Standards. Cattle: Meat: Nil; Milk: Nil. Horses: Meat: Nil Disposal: Dispose of empty container or expired product by wrapping with Storage: Store below 25 C (air conditioning). Protect from light. In-use shelf life: 11 weeks from initial broaching. Equine Metronidazole PASTE APVMA This product Approval is not No. registered, 68303/58052 but is (Australia) supplied under APVMA Permit per Read the permit before using. For the treatment of protozoal and anaerobic bacterial infections caused by metronidazole-sensitive organisms in horses Metronidazole 500mg/g For the treatment of infections in horses caused by anaerobic bacteria sensitive to metronidazole. Precautions DO NOT USE in animals with renal or hepatic disorders or dysfunction. Metronidazole is relatively non-toxic, however, over-dosage or prolonged treatment beyond the specified five days may result in reversible neurological depression, ataxia and impairment of the hepatic function. Horses - Administer orally. Give 10g metronidazole (20g Equine Metronidazole Paste) per 500kg bodyweight every 12 hours for 5 days or as directed by a veterinarian. The recommended dose is 20mg of metronidazole per kg of bodyweight per 12 hours. Insufficient data is available on use in pregnant horses to recommend the use of the product during pregnancy. Meat Withholding Period: NOT TO BE USED in horses intended for human consumption. with Storage: Store below 30 C (Room Temperature). Protect from light kg

14 Antibiotic Antibiotic Enro 50 Injectable Solution For the treatment of diseases caused by susceptible bacterial pathogens in dogs and cats Enro 100 Injectable Solution ACVM Act 1997 No.A11232 Anti-infective agent for the therapy of specific diseases caused by susceptible bacteria ACTIVE 100 mg/ml ENROFLOXACIN Enrofloxacin 50 mg/ml 100mL 50mL single Single vial Vial Description Enrofloxacin is a synthetic drug from the class of the quinolone carboxylic acid derivatives, also known as fluoroquinolones. It has antibacterial activity against a broad spectrum of Gram negative and Gram positive bacteria, including Mycoplasma. (See Table 1). It is rapidly absorbed from the digestive tract, penetrating into all measured body tissues and fluids (See Table 2). Enrofloxacin has the chemical name 1-cyclopropyl-7-(4-ethyl- 1-piperazinyl)-6-fluoro-1, 4- dihydro-4-oxo-3-quinolinecarboxylic acid. It is presented as an injection. Primary indications for use in the dog and cat are: Urinary tract infections including infections with E.coli, Proteus spp., Klebsiella spp., Pseudomonas aeruginosa, Staph spp., and Group D Streptococcus. Respiratory infections, including infections with E. coli, Streptococcus spp., Pasteurella spp., Klebsiella spp., Pseudomonas spp., Bordetella bronchiseptica, Staphylococcus spp. Deep pyodermas caused by Staph. intermedius including those infected with secondary invaders. Wounds, abscesses and discharging sinuses. Randlab Enrofloxacin 50 is especially useful in cats for treating serious antibiotic resistant infections of the respiratory tract or genito-urinary system, particularly chronic urinary tract infections. In cats it is also useful for deep pyodermas, osteomyelitis and Gram negative septicaemias. Randlab Enrofloxacin 50 may also be used in exotic animals (small mammals, reptiles and avian species) for the treatment of bacterial infections of the alimentary and respiratory tracts where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice. DO NOT use in food producing species of animals. FOR USE ONLY in companion animals where culture and sensitivity testing indicate no suitable alternative. Contraindications Dogs: Based on the studies discussed below under the section on Animal Safety, the use of enrofloxacin is contraindicated in dogs during the rapid growth phase. Randlab Enrofloxacin 50 should not be used in dogs under one (1) year of age. Giant breeds may be in the rapid growth phase for up to 18 months. Care should be used in treating individuals of these breeds with Randlab Enrofloxacin 50 when they are younger than 18 months. Cats: Randlab Enrofloxacin 50 should not be used in cats less than 12 weeks of age. The safe use of enrofloxacin in breeding female cats has not been established. Dosage Dogs & Cats The optimum dose of Randlab Enrofloxacin 50 in dogs and cats is 5 mg/kg of body weight (1 ml per 10 kg bodyweight) administered once daily. Randlab Enrofloxacin 50 Injection should be administered subcutaneously and normal sterile precautions should be taken. In simple infections, Randlab Enrofloxacin 50 should be given for 2-3 days beyond the cessation of clinical signs. Randlab Enrofloxacin 50 Injection may be used as the initial dose. If no improvement is seen within five days, the diagnosis should be re-evaluated and a different course of therapy considered. In deep or complex infections, eg pyodermas, discharging sinuses, extended courses may be required and progress should be regularly reviewed. DRUG INTERACTIONS: Dogs: Enrofloxacin has been administered to dogs concurrently with a wide variety of other products including anthelmintics (praziquantel, febantel, sodium disophenol), insecticides (fenthion, pyrethrins), heartworm preventatives (diethylcarbamazine), and other antibiotics (ampicillin, gentamicin sulfate, penicillin, dihydrostreptomycin). No incompatibilities with other drugs are known at this time except that fluoroquinolones may interfere with the metabolism of theophylline and related drugs (e.g. aminophylline) so the dosage of theophylline may need to be reduced. Cats: Enrofloxacin was administered concurrently with anthelmintics (praziquantel, febantel), a carbamate insecticide (propoxur), and another antibacterial (ampicillin). No incompatibilities with other drugs are known at this time. Storage: Store below 25 C (Air conditioning). Protect from light. ACTIVE 100 mg/ml ENROFLOXACIN Enrofloxacin 100 mg/ml For subcutaneous injection in cattle and intramuscular injection in pigs. Bacterial infections of bones in pigs and cattle. Mastitis in cows where the causative organisms have been established to be either E. coli or Pseudomonas. Appropriate intramammary treatment with another antibiotic should be used in combination with systemic treatment (other than oral) with Enrofloxacin 100. Infection of the male reproductive tract (prostatitis, vesiculitis, orchitis) in the bull. Other infections of cattle and pigs where poor tissue penetration by other antimicrobial drugs can be expected and where the condition is caused by a susceptible organism which is not expected to respond readily to other antibiotics. Indiscriminant use of antibiotics may lead to the development of resistance. Randlab Enrofloxacin 100 should be used in individual animals in line with the above recommendations. Treatment of groups of food producing animals is only recommended when culture and sensitivity testing indicate Randlab Enrofloxacin 100 is the only product likely to be effective. Chemistry: Randlab Enrofloxacin 100 Injectable Solution contains enrofloxacin, an anti-bacterial of the 4-quinolone group. Mode of action: Randlab Enrofloxacin 100 Injectable Solution inhibits the enzyme DNA gyrase which plays a major role in the replication of DNA. Inhibition of this enzyme leads to functional disturbances with blockage of certain stages in synthesis, resulting in death of the bacterium. This mode of action rules out cross resistance between Randlab Enrofloxacin 100 Injectable Solution and other anti-bacterials commonly used in veterinary medicine. Spectrum of activity: Randlab Enrofloxacin 100 Injectable Solution is active against a wide range of gram negative and gram positive bacteria and Mycoplasma species. Randlab Enrofloxacin 100 Injectable Solution is reserved for use for the following indications only: 1. Bacterial infections of bones in pigs and cattle. 2. Mastitis in cows where the causative organisms have been established to be either E. coli or Pseudomonas. Appropriate intramammary treatment with another antibiotic should be used in combination with systemic treatment (other than oral) with Randlab Enrofloxacin 100 Injectable Solution. 3. Infection of the male reproductive tract (prostatitis, vesiculitis, orchitis) in the bull. 4. Certain infections of cattle and pigs, in locations where poor tissue penetration by other antimicrobial drugs can be expected and where the condition is caused by a susceptible organism which is not expected to respond readily to other antibiotics. DOSAGE AND ADMINISTRATION Cattle & Pigs: Basic Dose Rate: 2.5 ml per 100 kg bodyweight per day for 3 days. Severe respiratory Infections: 5.0 ml per 100 kg bodyweight per day for 3 days mL 100mL Single single vial Vial Meat Withholding Period: MEAT: Animals producing meat or offal for human consumption must not be sold for slaughter either during treatment or within 7 days of the last treatment. MILK: Milk intended for sale for human consumption must be discarded during treatment and for 168 hours (7 days) following the last treatment. It is an offence for users of this product to cause residues exceeding the relevant MRL in the New Zealand (Maximum Residue Limits of Agricultural Compounds) Food Standards. Storage: below 25 C (Air conditioning). Protect from light. Following withdrawal of the first dose, use the remainder of the vial within 28 days or discard the unused portion. Dispose of empty container by wrapping with paper and putting in garbage.

15 Wormers Wormers Rotamectin ORAL PASTE APVMA Approval No /6.42/0208 For the treatment and control of roundworms, tapeworms, bots and nematode skin lesions in horses Terminator Wormer ALLWORMER Paste for Horses Highly effective for the treatment and control of tapeworms and roundworms Active Constituents Praziquantel 140 mg/g Ivermectin 18.7 mg/g Pail of 50 x 6.42g syringes For the treatment and control of roundworm (including arterial larval stages of Strongylus vulgaris and benzimidazole resistant small strongyles), tapeworm, bots and skin lesions caused by Habronema and Draschia spp. (summer sores) and Onchocerca spp., microfilariae (cutaneous onchocerciasis) in horses. At the dosage rate of 1 ml per 100 kg bodyweight Rotamectin Oral Paste for Horses delivers 0.2 mg/kg of IVERMECTIN and 1.5 mg/kg of PRAZIQUANTEL and is indicated for the treatment and control of the following parasites in horses: Ascarids: Parascaris equorum (adult and immature) Bots: Gasterophilus spp. (oral and gastric stages) Hairworms: Trichostrongylus axei (adult) Intestinal Threadworms: Strongyloides westeri (adult) Large Mouth Stomach Worms: Habronema muscae (adult) Large and Small Strongyles: Strongylus vulgaris (adults and arterial larval stages), Strongylus edentatus (both adult and tissue stages), Strongylus equinus (adults) and Triodontophorus spp. (adults), Cyathostomum spp., Cylicocyclus spp., Cylicostephanus spp., Cylicodontophorus spp., Gyalocephalus spp. Lungworms: Dictyocaulus arnfieldi (adult and immature) Neck Threadworms: Onchocerca spp. (microfilariae) Pinworms: Oxyuris equi (adult and immature) Tapeworms: Anoplocephala perfoliata, Anoplocephala magna, Paranoplocephala mamillana (adult, immature, heads, segments). Rotamectin Oral Paste for Horses also controls skin lesions caused by Habronema and Draschia spp., cutaneous larvae (summer sores), and Onchocerca spp., microfilariae (cutaneous onchocerciasis). DOSAGE AND ADMINISTRATION: Given orally at the recommended dose rate of 1 ml/100 kg bodyweight the 6 ml syringe is capable of treating horses of weight up to 600 kg. Screw the plastic adjuster out to the weight of the horse, insert the syringe into the side of the horse s mouth between the front and back teeth and deposit the paste towards the back of the tongue by depressing the plunger quickly as far as it will go. Immediately raise the horse s head for a few seconds to ensure the full dose has been accepted. Develop a Regular Treatment Program All horses should be subject to regular worming to maintain good health and peak condition. Particular attention should be given to young horses and mares. Foals should be treated initially at 6 to 8 weeks of age and this treatment repeated regularly as required. Rotamectin Oral Paste for Horses is well suited to be the major product in your equine parasite control program. It is highly effective in the treatment and control of most types of equine helminths including tapeworms, gastrointestinal, cutaneous and pulmonary nematod es and bots of horses of any age. With a regular treatment program the chances of verminous arteritis and colic caused by S. vulgaris will be reduced. Consult a veterinarian when developing a worm control program to suit your needs. Safety in Using: Rotamectin Oral Paste for Horses displays a wide safety margin at the recommended dose rate of 1 ml/100 kg bodyweight. Rotamectin Oral Paste for Horses may be used in both young foals to very old animals. Mares may be treated at any stage of pregnancy and fertility will not be affected in either sex. Safety Directions Harmful if swallowed. Will irritate the eyes and skin. Avoid contact with eyes and skin. Wash hands after use. Protection of Wildlife, Fish, Crustaceans and the Environment: Ivermectin is extremely toxic to aquatic species. Do not contaminate dams, rivers, streams or other waterways with the chemical or used container. Meat Withholding Period: DO NOT USE less than 28 days before slaughter for human consumption. Disposal: Dispose of empty container and syringe by wrapping with Storage: Store below 30 C (Room Temperature). Protect from light. Abamectin 3.7 mg/g Praziquantel 46.2mg/g 100mL single vial Terminator Wormer Allwormer Paste for Horses is highly effective against tapeworms and gastrointestinal, cutaneous and pulmonary nematodes and bots of horses of all ages. Regular treatment will reduce the chances of verminous arteritis and colic caused by Strongylus vulgaris. Terminator Wormer Allwormer Paste for Horses may be safely used on horses of all ages. Mares may be treated at any stage of pregnancy. Stallions may be treated without adversely affecting their fertility. At the recommended dose level of 1mL per 20kg bodyweight, Terminator Wormer Allwormer Paste for Horses controls the following parasites: Tapeworms: Anoplocephala perfoliata, Anoplocephala magna*, Paranoplocephala mammillana* (adult and immature, heads and segments). Large Strongyles: Strongylus vulgaris (adults and arterial larval stages), Strongylus edentatus (adults and tissue stages), Strongylus equinus (adults) and Triodontophorus spp (adults). Small Strongyles: including benzimidazole resistant strains (adult and immature) Cyathostomum spp, Cylicocylus spp, Cylicostephanus spp, Cylicodontophorus spp, Gyalocephalus spp. Pinworms: Oxyuris equi (adult and immature). Ascarids: Parascaris equorum (adult and immature). Hairworms: Trichostrongylus axei (adult). Large Mouth Stomach Worms: Habronema muscae (adult). Neck Threadworms: Onchocerca* spp (microfilariae). Bots: Gasterophilus spp (oral and gastric stages). Lungworms: Dictyocaulus arnfieldi (adult and immature). Intestinal Threadworms: Strongyloides westeri (adult). Terminator Wormer Allwormer Paste for Horses also effectively controls skin lesions caused by Habronema* and Draschia* spp cutaneous larvae (summer sores) and microfilariae of Onchocerca* spp (cutaneous onchocerciasis). * These parasites have not been recorded in New Zealand. All horses should be included in a regular parasite programme, with particular attention paid to mares, foals and yearlings. Because reinfection is common, treatment must be repeated routinely for effective control. Consult your veterinarian for a control programme to meet your needs. Dose: Each weight marking on the syringe plunger will deliver 0.2 mg/kg Abamectin mg/kg Praziquantel sufficient to treat 100kg bodyweight. The total contents of the syringe are sufficient to treat 600kg of bodyweight. Administration: Turn the ring on the plunger to the appropriate bodyweight setting. Insert the syringe into the side of the horse s mouth, in the gap between the front and back teeth. Advance the plunger as far as it will go, depositing the paste on the rear of the tongue. Immediately raise the horse s head for a few seconds after dosing, to ensure the full dose has been swallowed. Safety Directions May be harmful if swallowed. Abamectin may affect development and/or reproduction. Abamectin may have effects on or via lactation. Handle with care. Meat Withholding Period: Horses producing meat or offal for human consumption must not be sold for slaughter within 63 days of last treatment. with Storage: Store below 30 C (Room Temperature). Protect from light

16 Breeding Breeding Ovu-Mate 1 LITRE /125mL APVMA Approval No /51503 (Australia) ACVM No. A10159 (New Zealand) SENASA No (Argentina) To regulate oestrus in horses Altrenogest 2.2 mg/ml in a vegetable oil solution 125mL 1 litre For regulation and control of the breeding cycle of mares and the maintenance of pregnancy in habitually aborting mares, or mares at risk of early abortion. To induce ovulatory oestrus early in the breeding season in mares where some follicular activity exists. For the suppression of oestrus either during prolonged oestrus or in normally cycling mares. For the control of the ovarian cycle in the breeding mares to allow the most efficient use of the stallion. Dosage for oral administration. Administer 1 ml OVU-MATE per 50 kg bodyweight (equivalent to mg Altrenogest per kg) daily (12.5 ml per 625 kg mare). 1. FOR REGULATION AND CONTROL OF THE BREEDING CYCLE OF MARES For the induction of ovulatory oestrus or to induce cyclical ovarian activity in mares with some follicle activity early in the breeding season: administer Ovu- Mate daily for 10 consecutive days. For the suppression of oestrus in normally cycling mares: administer Ovu- Mate daily for 15 consecutive days. For the suppression of prolonged oestrus: administer Ovu-Mate daily for 10 consecutive days. To control the breeding cycle of mares to allow efficient use of the stallion: administer Ovu-Mate daily for 15 consecutive days. 2. FOR THE TREATMENT OF HABITUALLY ABORTING MARES, OR MARES AT RISK OF EARLY EMBRYONIC DEATH OR ABORTION Administer Ovu-Mate daily, from the 2nd or 3rd day after ovulation in the mated or inseminated mare, continuing until day 120 of gestation. NOTE: Ultrasound scanning to confirm pregnancy is recommended on day 14 or 15 after ovulation. If the mare is nonpregnant, it is advised to cease Ovu-Mate administration and to administer an injection of prostaglandin F2 to destroy any luteal tissue that may still be present, allowing the mare to return to oestrus and be re-mated. Contraindications This product is not indicated for use in male horses. This product is contraindicated for use in mares suffering from uterine infections. Precautions Unused feed must be destroyed and not given to any other animals. Ovu-Mate must be added to the feed immediately prior to consumption and not stored. Safety Directions Product is harmful if absorbed by skin contact, inhaled or swallowed. Avoid contact with eyes and skin. Do not inhale. When using the product wear rubber gloves. After use and before eating, drinking or smoking, wash hands, arms and face thoroughly with soap and water. After each day s use wash gloves. Care should be taken to avoid contact between the solution and women of child bearing age. Meat Withholding Period: DO NOT USE less than 28 days before slaughter for human consumption. regarding medication should be observed. Additional information is listed in the Material Safety Data Sheet available from RANDLAB AUSTRALIA in Australia phone (02) or in New Zealand (09) with Storage: Store below 25 C (Air conditioning). Protect from light. Ovu-Mate ALTRENOGEST INJECTION For use to delay the onset of oestrus and assist in maintaining pregnancy in horses ACTIVE Pentosan Altrenogest Polysulfate 50 mg/ml Sodium 250mg/mL 12 30mL x 6mL single Vials vial per outer carton and 50mL Single Vial Use contents within 28 days of first broaching vial. Discard unused portion. Store vial in an upright position. Dosage: As directed by prescribing veterinarian. Safety Directions Product is harmful if absorbed by skin contact or inhaled or swallowed. Avoid contact with eyes and skin. Do not inhale. When using the product wear rubber gloves. After use and before eating, drinking or smoking, wash hands, arms and face thoroughly with soap and water. After each day s use wash gloves. Care should be taken to avoid contact between the solution and women of child bearing age. Meat Withholding Period: NOT TO BE USED in horses that will be slaughtered for human consumption. Storage: Store below 25 C (Air Conditioning). Store in an upright position. Protect from light. Discard unused portion within 28 days of first broaching of vial

17 Breeding Breeding Ovu-Late INJECTION FOR CATTLE AND HORSES ACVM No. A10159 (New Zealand) For luteolysis of functional corpora lutea in cows and mares ACTIVE Pentosan Cloprostenol Polysulfate (as the sodium Sodium salt) 250mg/mL 250 µg/ml mL x 6mL & Vials 20mL per single outer vial carton and 50mL Single Vial Pharmacology Prostaglandins (PGs) are 20-carbon unsaturated fatty acids which consist of a cyclopentane ring with two aliphatic side chains. They are synthesised from free arachidonic acid in most major tissues in the body and serve as local hormones, acting on tissues near their site of synthesis. PGs are structurally classed into nine major groups, A to I, each containing subgroups denoted by the subscripts 1, 2 and 3. In domestic animals the most important PG appears to be PGF2. Cloprostenol is a functional synthetic analogue of the naturally occurring PGF2 dinoprost. Actions: In the reproductive system PGs play a role in ovulation, luteolysis, gamete transport, uterine motility, expulsion of foetal membranes, and sperm transport in both the male and female tracts. PGs are employed in reproductive therapeutics primarily for their potent luteolytic effects. PGF2 causes rapid regression of functional corpora lutea, with resultant rapid decline in progesterone production. Luteolysis is usually followed by ovarian follicular development and a return to oestrus with normal ovulation. In cattle oestrus occurs 2-4 days after luteolysis, and in mares 2-5 days after luteolysis. The early corpus luteum is insensitive to the effects of PG; in cattle and horses this refractory period spans the first 4-5 days post ovulation. The precise mechanism of PG-induced luteolysis is uncertain but may relate to blood flow changes in the uteoovarian vessels, inhibition of the normal ovarian response to circulating gonadotrophin, or stimulation of catalytic enzymes. PGF2 also has a direct stimulatory effect on uterine smooth muscle causing contraction, and a relaxant effect on the cervix. This product is contraindicated in mares suffering from acute or subacute disorders of the gastrointestinal or respiratory system. This product should not be used in pregnant animals when abortion or induced parturition is not the objective. This product should not be administered intravenously. Following withdrawal of the first dose, use the remainder of the vial within 28 days or discard the unused portion. Cows: Single or repeat doses of 2 ml (500 µg Cloprostenol) by intramuscular injection Oestrus Synchronisation Protocol: Day 0: Injection of 1 ml Cattle-Mate Injection 100 µg/ml Day 7: 2 ml Ovu-Late Injection Day 9: Injection of 1 ml Cattle-Mate Injection 100 µg/ml Insemination: 8-24 hours after 2nd injection of Cattle-Mate Injection. Mares: Less than 400 kg bodyweight: ml ( µg cloprostenol) by intramuscular injection. Greater than 400 kg bodyweight: 1-2 ml ( µg cloprostenol) by intramuscular injection. ADVERSE EFFECTS: Occasional side effects have been observed following intramuscular administration of PG. Such effects are generally transient and have little detrimental effect on the animal. In cows, increased body temperature and salivary secretion have been reported, usually associated with the administration of 5-10 times the recommended dose. Experimental administration of times the recommended dose to cattle resulted in signs of uneasiness, salivation and milk let-down, but no other adverse effects. Withholding Periods: Meat Withholding Period: (Cows): Do not use less than 1 day before slaughter for human consumption. (Horses): Not to be used in horses intended for human consumption. Milk Withholding Period: Nil Trade Advice: Export Slaughter Interval (ESI): This product does not have an ESI established. For advice on the ESI, contact the manufacturer before using this product. Caution: Women of child-bearing age, asthmatics or other people with bronchial disease should use extreme caution when handling cloprostenol as the drug may induce abortion or acute bronchoconstriction. Gloves should be worn when administering the drug. Cloprostenol is readily absorbed through the skin: Any cloprostenol contacting skin must be washed off immediately using soap and water. Storage: Store below 25 C (air conditioning). Protect from light. Following withdrawal of the first dose, use the remainder of the vial within 28 days or discard the unused portion. Dispose of empty container by wrapping with paper and putting garbage. Cattle-Mate Gonadorelin Injection ACVM No. A11104 (New Zealand) For the treatment of cystic ovaries, prevention of delayed ovulation and improvement of postpartum fertility in cattle ACTIVE Pentosan Gonadorelin Polysulfate (as acetate) Sodium 100 μg/ml 250mg/mL Pharmacology Gonadorelin is a synthetic decapeptide, identical to the endogenous Gonadotrophin Releasing Hormone (GnRH). GnRH is synthesised and secreted in a pulsatile manner by the hypothalamus and is transported via the hypothalamic-hypophyseal portal circulation to its site of action, the anterior pituitary. Actions Gonadorelin induces the synthesis and release of gonadotrophins from the anterior pituitary, such that LH and FSH are released from the pituitary shortly after gonadorelin administration. LH and FSH act on the ovary to stimulate maturation of ovarian follicles and ovulation. Pharmacokinetics Gonadorelin is rapidly absorbed from the site of the intramuscular injection 1. Following absorption, rapid distribution of Gonadorelin occurs with concentrations at the site of action as well as in the pineal gland, posterior pituitary, ovaries, liver and kidney, greater than concentrations in plasma. 1 The plasma half-life of gonadorelin is approximately 20 minutes in cattle. 1 Gonadorelin undergoes rapid metabolism by peptidase enzymes into smaller inactive peptides and amino acids. Metabolites are primarily excreted in urine and expired air. 1 Clinical Application Clinical applications for Cattle-Mate Gonadorelin Injection in cattle are as follows: Oestrus Synchronisation Oestrus synchronisation protocols involving the use of Prostaglandin F2 (PGF2 ) and Gonadotrophin Releasing Hormone (GnRH) have been subjected to extensive study in dairy herds around the world. Comparisons have been made between GnRH/PGF2 synchronisation programs and a variety of existing reproductive management programs of varying levels of intervention. GnRH/ PGF2 protocols have measured favourably against standard prostaglandin programs in terms of reproductive parameters such as pregnancy rate and calving to contraception interval. TREATMENT OF CYSTIC OVARIES Cystic ovaries are an important infertility problem in dairy cattle. Ovarian cysts may be single or multiple, and of follicular or luteal origin. Clinical signs of ovarian cysts include irregular oestrus cycles, anoestrus and nymphomania. Diagnosis of ovarian cysts is by rectal palpation of the structures on one or both ovaries. PREVENTION OF DELAYED OVULATION Delayed ovulation can result in reduced conception rates due to asynchrony between ova and sperm at the time of artificial insemination (AI). Administration of Cattle-Mate Injection stimulates an LH surge and consequently induces ovulation, thereby preventing the problem of delayed ovulation. IMPROVEMENT OF POSTPARTUM FERTILITY Resumption of normal ovarian cyclical activity in the early postpartum period is essential to minimise the calving to conception interval, or days open. Treatment of cows with Cattle-Mate Injection during the first 40 days of the postpartum period may initiate a resumption of cyclicity in acyclic cows, and reduce the incidence of postpartum ovarian disorders. Stability studies have demonstrated CATTLE-MATE Gonadorelin Injection is stable for at least 28 days following first use, providing aseptic technique is followed. Following withdrawal of the first dose, use the remainder of the vial within 28 days or discard the unused portion. Cattle: Injection to be given into the anterior half of the neck. Cystic ovaries: 5 ml (500 μg Gonadorelin) by intramuscular injection. Prevention of delayed ovulation: 2.5 ml (250 μg Gonadorelin) by intramuscular injection. Improvement of postpartum fertility: 2.5 ml (250 μg Gonadorelin) by intramuscular injection. Oestrus synchronisation: 1 ml (100 μg Gonadorelin) by intramuscular injection, for example: Day ml Cattle-Mate Injection Day ml Ovu-Late Injection (Cloprostenol as sodium salt 250 μg/ml) Day ml Cattle-Mate Injection Insemination hours after second GnRH. Medicinal Products, European Agency for the Evaluation of Medicinal Products (EMEA) mL x 6mL & Vials 20mL per single outer vial carton and 50mL Single Vial 1. Gonadotrophin Releasing Hormone (Gonadorelin) Summary Report. Committee for Veterinary Meat Withholding Period: MEAT: NIL, MILK: NIL Trade Advice: EXPORT SLAUGHTER INTERVAL (ESI): This product does not have an ESI established. For advice on the ESI, contact the manufacturer on before using this product. Storage: Store between 2 and 8 C (Refrigerate. Do not freeze). Protect from light.

18 Corticosteroid Anaesthetic Intra-Log INJECTION Medicaine Local Anaesthetic Injection For the treatment of inflammation and related disorders in dogs, cats and horses Precautions Not for use in horses intended human consumption. Intra-log Injection (Sterile Triamcinolone Acetonide Suspension) should not be used to alleviate pain or reduce inflammation arising from infectious states unless concomitant antimicrobial therapy is given. For local anaesthesia in horses Usage In Pregnancy The safety of most corticosteroid drugs for use during all stages of pregnancy has not been adequately established. However, clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, foetal death, retained placenta and metritis. Triamcinolone Acetonide 6 mg/ml 12 x 3mL vials Also for the management of acute arthritis, allergic and dermatologic disorders in dogs and cats Intra-log Injection (Sterile Triamcinolone Acetonide Suspension) is a highly potent synthetic glucocorticoid which is primarily effective because of its anti-inflammatory activity. The apparent analgesic effect is a result of the anti-inflammatory properties of the drug. Directions Depending on the nature of the condition, Intra-log Injection may be injected intramuscularly, intra-articularly or intra-synovially. The usual pattern of response is improvement of motion and decrease of pain within 24 hours, followed by diminution of swelling. Side Effects As with any corticosteroid, polydipsia or polyuria may occur with high dosage or frequent administration of triamcinolone acetonide. The likelihood of their occurrence may be minimised by giving as brief a course of corticosteroid therapy as possible, and by waiting for the reappearance of symptoms before repeating therapy. If polydipsia or polyuria should occur, therapy should be discontinued until these unwanted effects have disappeared; therapy should then be resumed at a lower dosage level. Additionally, corticosteroids administered to dogs, rabbits and rodents during pregnancy have resulted in cleft palate in offspring. Corticosteroids administered to dogs during pregnancy have also resulted in other congenital anomalies including deformed forelegs, phocomelia and anasarca. Therefore, before use of corticosteroids in pregnant animals, the possible benefits to the pregnant animal should be weighed against potential hazards to its developing embryo or foetus. : Intramuscular or subcutaneous injection: Dogs and Cats: 0.1 to 0.2 mg/kg bodyweight Horses: 12 to 18 mg. Intra-articular, intra-synovial injection Dogs and Cats: 1 to 3 mg Horses: 6 to 18 mg Meat Withholding Period: DO NOT USE in horses intended for human consumption. Storage: below 25 C (Air Conditioning). Do not freeze. Protect from light. ACTIVE Pentosan Prilocaine Polysulfate Hydrochloride Sodium 20 mg/ml 250mg/mL 12 6 x x 20mL 6mL Vials vials per outer carton and 50mL Single Vial Discard unused portion within 14 days of first broaching. For Surface and Regional Anaesthesia: Horses: Administer by subcutaneous injection as required up to a maximum of 20 ml. For Epidural Anaesthesia: Horses: Low Epidural: Administer up to a maximum of 12 ml. High Epidural: Administer up to a maximum of 150 ml. Meat Withholding Period: NOT TO BE USED in horses intended for human consumption. Storage: Store below 30 C (Room temperature)

19 36 High Performance Endectocide Joint Therapies UNDER DEVELOPMENT Respiratory Products Other Pro-Cardia 365 Injection once-a-year heartworm preventative for dogs For the 12 month prevention of heartworm disease in dog Moxidectin 100 mg/g Moxidectin 10 mg/ml when suspended according to directions 10mL, 20mL and 50mL vials For the control of larval and adult infections of canine hookworms at the time of treatment and for up to 4 months after treatment. Contents Each small pack contains: 1 vial containing 0.9 g Pro-Cardia 365 Injection microspheres (100 mg/g moxidectin). 1 vial containing at least 9 ml Pro- Cardia 365 Injection sterile vehicle (use only 8 ml when suspending). 1 transfer needle and syringe. 1 vent needle. Each large pack contains: 1 vial containing 4.5 g Pro-Cardia 365 Injection microspheres (100 mg/g moxidectin). 1 vial containing at least 44 ml Pro- Cardia 365 Injection sterile vehicle (use only 40 ml when suspending). 1 transfer needle and syringe. 1 vent needle. Precautions: Do not inject suspended product intravenously. Use aseptic technique at all times. In a small number of cases, there may be short-lived pain at the time of injection or slight transient (1-2 weeks) swelling at the site of injection. Allergic reactions such as anaphylaxis (facial and aural swelling, urticaria, vomiting) occur rarely and may require parenteral treatment with an antihistamine, a corticosteroid or adrenalin as appropriate. 2. Using the sterile 18 G x 1 inch needle and the sterile syringe provided, withdraw 8 ml of sterile vehicle from the vial labelled Pro-Cardia 365 Injection Sterile Vehicle. (There is more than the required 8 ml of vehicle supplied in the vial). 3. Insert the 25 G x ½ inch vent needle provided into the vial labelled Pro-Cardia 365 Injection Microspheres to act as a vent. 4. Transfer the sterile vehicle into the microsphere vial using the transfer needle and syringe. 5. Once the sterile vehicle has been added, remove the vent and transfer needles from the microsphere vial. Discard unused vehicle and needles (see disposal directions below). Do not leave the vent needle in the bottle after suspending. 6. Shake the microsphere vial thoroughly until an evenly mixed suspension is produced (for approximately 30 seconds). 7. Allow the suspension to stand for at least 10 minutes (preferably 30 minutes) to allow large air bubbles to dissipate. 8. Record the date of mixing on the microsphere vial. 9. Before every use, gently swirl the mixture to achieve a uniform suspension. The microspheres and sterile vehicle will gradually separate and sediment out on standing. 10. Use an appropriately sized sterile syringe with an 18 G or 20 G x 1 inch needle for administration. (A 20 gauge needle is recommended for dogs less than 20 kg, and an 18 gauge for those over 20 kg). Administer promptly after filling the syringe. If administration is delayed, gently rock the syringe prior to injection to maintain an even suspension of microspheres and ensure accurate dosing. 11. Store unused product under aseptic conditions at 2-8 C (Refrigerate. Do not freeze). Protect from direct light. The suspended product remains stable for 8 weeks under these storage conditions. Mixing Directions (Large Pack) Follow the same directions as those for the small vial, except that 40 ml of sterile vehicle should be transferred to the microsphere vial. Dosage & Administration Recommended for use in dogs from 12 weeks of age. Administer 1 ml of suspension per 20 kg body weight subcutaneously to provide a dose of 0.5 mg moxidectin/kg body weight. Rock the syringe to maintain the suspension and inject subcutaneously under the loose skin on the dorsum or the side of the neck, anterior to the scapula. To maintain full protection in adult dogs, repeat the treatment every 12 months. with Discarded needles should be immediately placed in a designated and appropriately labelled sharps container. Please note instruction leaflet and cardboard carton only are recyclable. Vetedine OINTMENT APVMA Approval No /43528 (Australia) For the treatment and prevention of wound and skin infections caused by bacteria and fungi in horses, dogs and cats Povidone-Iodine 100 mg/g (equivalent to 10 mg/g available Iodine) Vetedine Ointment is a Povidone-Iodine ointment (known as an Iodophor) with potent prolonged antibacterial, antifungal and virucidal activity on contact, suitable for topical disinfection and antisepsis in horses, cattle, swine, sheep and dogs with minor cuts and abrasions, burns and puncture wounds to skin. It acts by releasing iodine slowly. PVP iodine is as effective as iodine against a broad spectrum of disease causing microorganisms, but it is less irritating to skin, and any stains are water washable. There has been no reported resistance to PVP iodine in human or animal medicine. It is nonsensitising and does not cause pain on application to wounds mucous membranes. It forms a film to protect open wounds, and is soluble in water. PVP Iodine is particularly effective in treating mixed skin infections, wound cleansing, treatment of burns and ulcers, and in skin antisepsis. It does not delay healing or granulation, and does not lose antimicrobial activity in the presence of organic matter such as blood, pus, oils, soaps, etc. Use Vetedine Ointment as an aid in the treatment or prevention of local infections in wounds, abscesses, burns and fungal infections such as Ringworm, disinfection of the navel, horn removal, castration, disinfection prior to surgery, girth galls, abrasions and puncture wounds. Apply to the affected area twice daily or as directed by the veterinary surgeon. Care should be exercised using iodine on extensive wounds or deep burns especially over extended periods. Does not permanently stain skin or natural fibres. Wash with soap and water to remove. Vetedine Ointment Has prolonged activity, even in the presence of pus or blood Does not stain. Wash off with water Does not delay wound healing or granulation Does not sting or irritate wounds Does not sensitise tissues Lacks resistance by any microorganisms Can be bandaged without danger of burns or irritation Has prolonged germicidal action Has no odour Has rapid action, even in presence of blood, pus, oils, soap, etc. Forms an adherent film over wounds The characteristic colour delineates the treated area Meat Withholding Period: Nil. Racing/Event Withholding Period: Nil. Vetedine Ointment contains no prohibited substances. If in doubt, always check with local racing jurisdiction. Storage: Before suspending, store below 30 C (room Mixing Directions (Small Pack) temperature). Product suspended for injection as directed may be stored for up to 8 weeks between 2 and 8 C 1. Use only the Pro-Cardia 365 Injection sterile vehicle provided in this pack. Do not (Refrigerate. Do not freeze). Storage: Store below 30 C (room temperature). substitute with other solutions of any type. Pro-Cardia, Stilator and Mobitor are products registered to Ferrari Animal Health, a subsidiary of Randlab Veterinary Medicines Pty Ltd g jar

20 Bone Modifier Zoldronic Acid Bisphosphonate Injection for Horses A Commitment to Excellence A bisphosphonate for animals with skeletal complications Zoledronic acid (as monohydrate) 0.45 mg/ml 100mL vial Zoledronic acid is a bisphosphonate given intravenously to prevent skeletal fractures. Bisphosphonates are therapeutic agents with strong affinity for bone and markedly inhibit osteoclast activity. Zoledronic acid is used in the treatment of skeletal diseases associated with high osteoclast activity and accelerated bone turnover. A recent study showed Zoledronic acid at a dose of 0.057mg/kg improved lameness score or resolution of clinical signs in 9 of 10 horses with fragility disorder (silicate-associated osteoporosis) and an improvement on scintigraphic evaluation was observed in 8 of 10 horses. No adverse effects were observed. Side Effects And Overdosage The safety of this product has not been fully tested. Zoledronic acid is rapidly processed by the kidneys, consequently, its administration is not recommended for animals with reduced renal function or kidney disease. Precautions and Contraindications DO NOT USE in horses with reduced renal function. DOSAGE: HORSES: Dose: Administer entire contents of this vial (100ml) to one horse, with 0.9% Sodium Chloride solution (450ml) by slow intravenous injection in not less than minutes. One vial (100ml) is sufficient to treat horse weighing kg. This will result in a dose of mg/kg. Zoledronic acid. One dose annually is recommended. Meat Withholding Period: DO NOT USE in horses intended for human consumption. Storage: Store between 2 C and 8 C. (Refrigerate. Do not freeze)

21 Supplements Respiratory Supplements Products Supplements Supplements Over-the-counter products for the continual wellbeing of your horse s health Randlab supplements contain no prohibited substances - contact us for more information Supervites 15kg Pail Premium electrolytes, vitamins and antioxidants supplement for horses. S Each 60mL syringe provides: L-Leucine g L-Isoleucine g L-Valine g BC5aa Paste 60mL Syringe Branch chain amino acids for optimum muscle recovery. L-Glutamine g L-Carnitine g Aniseed oil... 25g/L S Each 30g dose provides; Sodium g Potassium g Calcium g Magnesium g Chloride g Phosphate g Sulphate g Bicarbonate g Thiamine (B1) g Riboflavin (B2) g Niacin (B3) g Pyridoxine (B6) mg Vitamin B mg Choline g Folic acid mg Inositol g Vitamin E g Electrolene Paste 90g Syringe Oral Electrolyte paste with B-Group Vitamins, Vitamin E and Folic Acid for hard working or dehydrated horses. S Each g contains: Sodium mg Chloride mg Potassium mg Magnesium mg Calcium mg Zinc mg DL- -tocopheryl acetate (Vitamin E) mg 40 Folic acid mg Thiamine mononitrate (Vitamin B1) mg Riboflavin (Vitamin B2) mg Nicotinamide (Vitamin B3) mg Calcium pantothenate (Vitamin B5) mg Pyridoxine hydrochloride (Vitamin B6) mg Cyanocobalamin (Vitamin B12) mg Alljoints 5kg Pail Supports joint cartilage repair and maintenance in horses. S Each 50g daily dose contains: Collagen Hydrolysate mg Glucosamine Sulphate mg Glucosamine HCI mg Dicalcium Phosphate mg Apple Flavour...100mg Kentucky Gold Saline Drench 300g Sachet Electrolytes, B vitamins and energy saline drench for horses. S Each 300g sachet provides: Vitamin B Complex and balanced electrolytes Sodium, Potassium, Magnesium, Calcium, Chloride, Sulphates, Propionate, Acetate, Citrate and Vitamin E 2,000iu all in rapid and completely water soluble form. 41

22 Company Information Company Information Partnering For Success Global Growth At Randlab we believe true innovation comes from finding a solution before the problem is known. It s that kind of thinking that has created some of the most innovative, consumer friendly and enhanced treatments in veterinary medication, and it s this kind of focus that gives our clients an advantage. Growing with the Equine Veterinarian Community RESEARCH ENGAGING WITH CUSTOMERS CONSULTATION & PROMOTION IMPROVING AND EVOLVING CONSTANTLY TO MARKET Delivering Innovative Veterinary Medicines IDENTIFYING PROBLEMS AND FOCUSING ON SOLUTIONS TESTING AND EVALUATION DEVELOPMENT REGISTRATION COMPLIANCE AND REGULATORY Randlab s people are the most important factor to the success of our company, as it s what sets us apart from our competitors. An g e l i s Va s i l i, c e o 2004 Randlab Established in Sydney, Australia 2005 Research and Product Development in progress Driving better solutions for our customers Executing a global strategy 2007 Arthropen Vet 250 launched to market 2007 Randlab opens office in New Zealand Innovative veterinary medication solutions Helping our clients win 2009 Randlab attains Bain Fallon Memorial Silver Sponsor Status Bringing new products to market 2009 Innovative Equinate IV launched to market 2010 Randlab expands to larger factory to meet increased demand 2011 Supplements program enjoys continued success Managed medication programs Responding to regulatory changes 2014 Cattle-Mate and Ovu-Late meet regulatory approval in New Zealand 2012 Randlab adds agents in Malaysia and Singapore 2016 Over 40 products for sale globally 2016 Ulcershield passes Australian Regulatory Approvals Taking Local Success... Randlab is Australia s leading provider of equine veterinarian medicines for competition and recreational horses....to the World Randlab s business outlook globally is focused on growth and is driven by the need for our innovative veterinary medicines

23 Our Commitment Company Respiratory Information Products Randlab s Commitment to Veterinarians More Information Randlab supports equine veterinarians globally through support for continuing education events and providing innovative medicines at an affordable price. Supporting the key equine veterinary bodies in their respective countries. Providing Gastroscoping equipment for Equine Practice client days Providing Innovative products at an affordable price. Head Office Randlab Australia Head Office 7/85 Alfred Road Chipping Norton NSW 2170 Australia Phone (+61-2) Fax (+61-2) info@randlab.com.au Quality Our commitment to quality starts with the sourcing of only the finest raw materials and pharmaceutical grade ingredients for our products. We manufacture all of our products in facilities that are GMP approved through the Australian regulator, the APVMA. We carefully follow each batch of our manufactured product with strict Quality Assurance (QA) testing in government approved independent laboratories. Worldwide product registrations (where available) are part of our quality control and also serve to protect our innovative medicines. Service We have a simple philosophy with our service the customer comes first and the relationship is of utmost value to Randlab. We pride ourselves on the personal level of service that we offer our veterinarian, wholesaler and institutional partners throughout the world. If you have yet to use our products, contact us to discuss how our products and service can help you and your business. Value Randlab understands that owning horses for whatever need can be expensive. We also understand and support equine veterinarians by providing our products at a cost competitive level. Care Randlab cares very deeply about its involvement in the equine and veterinary community globally. We are active in selected equine and veterinary charities throughout the world. You can find Randlab at every major equine veterinary conference and further education event. HOW TO ORDER RANDLAB Veterinary Medicines Established orders@randlab.com.au or info@randlab.com.au Call Debra in the Sydney office (61-2) Fax your order (61-2)

24 International Contacts Respiratory Products Notes International Contacts Randlab New Zealand 19 Victoria Street, Cambridge New Zealand Phone: (+64-7) Randlab Asia Pte Ltd 01-05, 19 Woodlands Industrial Park E1 Singapore Phone: (+65) Randlab UAE Ground Floor, Alzarooni Building Khalid Bin Walseed Street Dubai UAE Phone: (+971) Eu Randlab Sprl 24 Rue Tayant Ransart 6043 Belgium Phone: (+32) Rest of the World 7/85 Alfred Road Chipping Norton NSW 2170 Australia Phone: (+61-2) Fax: (+61-2) Find us on Facebook: Randlab Global First Aid Statement: Contact your Poisons Information Centre in your local country to obtain information regarding suitable treatment. Australian Made Australian Owned 46 Where noted, all products are either trademark or registered trademarks of Randlab Australia Pty Ltd. 47